Analysts Set Expectations for Delcath Systems Q1 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Delcath Systems in a research report issued to clients and investors on Friday, May 23rd. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $0.13 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $29.00 target price on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems' Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.25 EPS and Q4 2026 earnings at $0.34 EPS.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million.

Separately, Wall Street Zen raised shares of Delcath Systems from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 24th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Delcath Systems presently has an average rating of "Buy" and a consensus target price of $24.00.

Delcath Systems Stock Performance

Shares of Delcath Systems stock traded down $0.76 on Monday, hitting $16.31. The company had a trading volume of 32,233 shares, compared to its average volume of 464,324. The stock has a 50 day moving average of $13.26 and a 200-day moving average of $13.12. The stock has a market capitalization of $567.84 million, a price-to-earnings ratio of -12.09 and a beta of 0.72. Delcath Systems has a 1 year low of $6.33 and a 1 year high of $18.23.

Institutional Trading of Delcath Systems

Hedge funds have recently bought and sold shares of the stock. Baader Bank Aktiengesellschaft purchased a new stake in Delcath Systems during the 4th quarter valued at $204,000. Principal Financial Group Inc. boosted its stake in shares of Delcath Systems by 28.8% during the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock valued at $1,387,000 after purchasing an additional 25,736 shares in the last quarter. Private Advisor Group LLC purchased a new stake in shares of Delcath Systems during the 4th quarter worth $153,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Delcath Systems in the 4th quarter valued at about $156,000. Finally, Quantbot Technologies LP purchased a new position in Delcath Systems in the fourth quarter worth $66,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.